National Comprehensive Cancer Network



About NCCN

NCCN Flash Update: NCCN Guidelines Updated

Flash Update Sent September 16, 2011

NCCN has published updates to the NCCN Guidelines and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Hodgkin Lymphoma. These NCCN Guidelines are currently available as Version 3.2011.

  • Brentuximab vedotin was added as a treatment option for patients with relapsed or progressive disease with the following footnote: "Brentuximab vedotin is a treatment option for patients who have failed HDT/ASCR or at least 2 prior multi-agent chemotherapy regimens."


Flash Update Sent September 12, 2011

NCCN has published updates to the NCCN Guidelines and the NCCN Compendium® for Breast Cancer Risk Reduction. These NCCN Guidelines are currently available as Version 3.2011.

  • For postmenopausal women desiring risk reduction therapy, exemestane has been added to the list of risk reduction agents as a category 1 option with a footnote stating, "Other aromatase inhibitors have shown prevention of contralateral breast cancer and there are ongoing clinical trials."


For the complete updated version of these and all NCCN Guidelines, visit NCCN.org.

 

Quick Links


About NCCN| NCCN Member Institutions| Patient Resources| NCCN Foundation| Privacy Policy| Legal Notices| Contact Us

275 Commerce Drive, Suite 300, Fort Washington, PA 19034 • 215.690.0300 • Fax: 215.690.0280
Copyright © 2013 National Comprehensive Cancer Network, All Rights Reserved